BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Samy N, Reichhardt D, Schmidt D, Chen LM, Silbernagl G, Vidojkovic S, Meyer TP, Jordan E, Adams T, Weidenthaler H, Stroukova D, De Carli S, Chaplin P. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial. Vaccine 2020;38:2608-19. [PMID: 32057576 DOI: 10.1016/j.vaccine.2020.01.055] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Shan J, Britton PN, King CL, Booy R. The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review. Influenza Other Respir Viruses 2021;15:539-51. [PMID: 33764693 DOI: 10.1111/irv.12850] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Endt K, Wollmann Y, Haug J, Bernig C, Feigl M, Heiseke A, Kalla M, Hochrein H, Suter M, Chaplin P, Volkmann A. A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection. Front Immunol 2022;13:841471. [DOI: 10.3389/fimmu.2022.841471] [Reference Citation Analysis]
3 Stephens LM, Varga SM. Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population. Vaccines (Basel) 2021;9:624. [PMID: 34207770 DOI: 10.3390/vaccines9060624] [Reference Citation Analysis]
4 Blunck BN, Rezende W, Piedra PA. Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine. Expert Rev Vaccines 2021;20:351-64. [PMID: 33733995 DOI: 10.1080/14760584.2021.1903877] [Reference Citation Analysis]
5 Yoshikawa T. Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers. Vaccine 2021;39:6174-81. [PMID: 34521550 DOI: 10.1016/j.vaccine.2021.09.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Volkmann A, Williamson AL, Weidenthaler H, Meyer TPH, Robertson JS, Excler JL, Condit RC, Evans E, Smith ER, Kim D, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG. The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. Vaccine 2021;39:3067-80. [PMID: 33077299 DOI: 10.1016/j.vaccine.2020.08.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Andrade CA, Pacheco GA, Gálvez NMS, Soto JA, Bueno SM, Kalergis AM. Innate Immune Components that Regulate the Pathogenesis and Resolution of hRSV and hMPV Infections. Viruses 2020;12:E637. [PMID: 32545470 DOI: 10.3390/v12060637] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
8 Isaacs A, Cheung STM, Thakur N, Jaberolansar N, Young A, Modhiran N, Bailey D, Graham SP, Young PR, Chappell KJ, Watterson D. Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates. Viruses 2021;13:1942. [PMID: 34696372 DOI: 10.3390/v13101942] [Reference Citation Analysis]
9 Jordan E, Lawrence SJ, Meyer TPH, Schmidt D, Schultz S, Mueller J, Stroukova D, Koenen B, Gruenert R, Silbernagl G, Vidojkovic S, Chen LM, Weidenthaler H, Samy N, Chaplin P. Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine. J Infect Dis 2021;223:1062-72. [PMID: 32726422 DOI: 10.1093/infdis/jiaa460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Henning L, Endt K, Steigerwald R, Anderson M, Volkmann A. A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge. Front Immunol 2020;11:598847. [PMID: 33542715 DOI: 10.3389/fimmu.2020.598847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 van den Eshof BL, Medfai L, Nolfi E, Wawrzyniuk M, Sijts AJAM. The Function of Immunoproteasomes-An Immunologists' Perspective. Cells 2021;10:3360. [PMID: 34943869 DOI: 10.3390/cells10123360] [Reference Citation Analysis]
12 Biagi C, Dondi A, Scarpini S, Rocca A, Vandini S, Poletti G, Lanari M. Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines. Vaccines (Basel) 2020;8:E672. [PMID: 33187337 DOI: 10.3390/vaccines8040672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
13 Pérez P, Martín-Acebes MA, Poderoso T, Lázaro-Frías A, Saiz JC, Sorzano CÓS, Esteban M, García-Arriaza J. The combined vaccination protocol of DNA/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses. Emerg Microbes Infect 2021;10:1441-56. [PMID: 34213405 DOI: 10.1080/22221751.2021.1951624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Šantak M, Matić Z. The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses—Not Just Another Brick in the Viral Nucleocapsid. Viruses 2022;14:521. [DOI: 10.3390/v14030521] [Reference Citation Analysis]
15 Kotomina T, Isakova-sivak I, Stepanova E, Mezhenskaya D, Matyushenko V, Prokopenko P, Sivak K, Kiseleva I, Rudenko L. Neutralizing epitope of the Fusion Protein of Respiratory Syncytial Virus Embedded in the HA Molecule of LAIV Virus is not Sufficient to Prevent RS Virus Pulmonary Replication but Ameliorates Lung Pathology following RSV Infection in Mice. TOMICROJ 2020;14:147-56. [DOI: 10.2174/1874285802014010147] [Reference Citation Analysis]